Form 4: Grace Therapeutics Director Kottayil Acquires Stock Options

George Kottayil, a director at Grace Therapeutics, acquired stock options for 10,000 shares at an exercise price of $2.72 on May 9, 2025.

Summary

• On May 9, 2025, George Kottayil, a director of Grace Therapeutics, Inc., acquired stock options for 10,000 shares.
• The exercise price for these options is $2.72 per share.
• 50% of the options vest immediately, and the remaining 50% vest in equal monthly installments until September 30, 2025, contingent upon continuous service.
• The options expire on May 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain any alarming or negative information. It's a neutral event with a slightly positive implication for director alignment with shareholder interests.

Future Outlook

NA

Industry Context

This is a standard practice for compensating and incentivizing directors in publicly traded companies. Stock options align the director's interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, director, Grace Therapeutics, GRCE, Kottayil, beneficial ownership, securities